Bausch and Lomb rewards visa is a scam. I used the visa before the expiration date. The product was the wrong product. The retailer refunded the purchase price to the rewards card (in violation of ...

RBC Capital analyst Douglas Miehm raised the firm’s price target on Bausch + Lomb (BLCO) to $23 from $20 and keeps an Outperform rating on the shares ahead of its Q3 results. The firm is ...

(Bloomberg) -- Banks and private credit firms are competing to provide at least $5 billion of debt financing to help fund a potential buyout of Bausch + Lomb, according to people with knowledge of ...

TPG and Blackstone have partnered to bid for eye care company Bausch + Lomb Corporation, according to sources cited by the Financial Times. If successful, the transaction could become one of the ...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S ...